HIA方案治疗复发难治性急性髓系白血病2例并文献复习
摘要
目的探讨以HIA方案化疗对复发难治性急性髓系白血病的疗效。方法采用以HIA方案治疗复发难治性急性髓系白血病2例,化疗2个疗程。结果 2例均完全缓解。结论 HIA方案对复发难治性急性髓系白血病患者是有效的。
出处
《浙江实用医学》
2013年第3期227-228,共2页
Zhejiang Practical Medicine
参考文献12
-
1Estey E H. Treatment of relapsed and refractory acute myeloidleukemia. Leukemia,2000,14 : 476.
-
2Yamada K, Furusawa S, Saito K, et al. Concurrent use of granulocytecolony - stimulating factor with low - dose cytosine arabinoside andaclarubicin for previously treated acute myelogenous leukemia : a pilotstudy. Leukemia, 1995,9(1) : 10.
-
3Hashmi K U,Khan B,Ahmed P,et al.FLAG — IDA in the treatment ofrefractory/relapsed acute leukemias: single centre study. J Pak MedAssoc,2005,55(6) :234.
-
4Montesinos P,Rubia Jdl,Orti G,et al.FLAG- IDA regimen (fludara-bine,cytarabine,idarubicin and G - CSF) in the treatment of patientswith high2 risk acute myeloid leukemia and myelodysp lastic syn-dromes .Blood (ASH Annual Meeting Abstract),2007,110:2866.
-
5Yavuz S,Paydas S, Disel U,et al. IDA - FLAG regimen for the therapyof primary refractory and relapse acute leukemia : a single - centerexperience . Am J Ther,2006,13 : 389.
-
6急性髓系白血病(复发难治性)中国诊疗指南(2011年版)[J].中华血液学杂志,2011,32(12):887-888. 被引量:90
-
7Staber P B,Linkesch W,Zauber D,et al. Common alterations in geneexpression and increased proliferation in recurrent acute myeloidleukemia. Oncogene,2004,23(4) :894.
-
8Hur M,Chang Y H,Lee D S, et al. Immunophenotypic and cytogeneticchanges in ante leukemia at relapse. Clin Tah Haematol, 2001, 23(3):173.
-
9唐加明,孟凡义,陈安薇.难治性急性髓系白血病(M_(2a))的基因表达谱[J].癌症,2005,24(6):676-679. 被引量:1
-
10Michieli M, Dminni D, Ermacora A, et al. P - glycoprotein,lung resis-tance -related protein and multidrug resistance associated protein inde novo acute non - lymphocytic leukemias : biological and clinicalimplications. Br J Haematol,1999,104(2) : 328.
二级参考文献16
-
1Hur M, Chang YH, Lee DS, et al. Immunophenotypic and cytogenetic changes in acute leukemia at relapse [J]. Clin Lab Haematol, 2001,23(3): 173-179.
-
2Michieli M, Dmiani D, Ermacora A, et al. P-glycoprotein,lung resistance-related protein and multidrug resistance associated protein in de novo acute non-lymphocytic leukemias:biological and clinical implications [J]. Br J Haematol, 1999,104(2): 328-335.
-
3van den Heuvel-Eibrink MM, Wiemer EAC, Prins A, et al.Increased expression of the breast cancer resistance protein (BCRP) in relapsed or refractory acute myeloid leukemia (AML) [J]. Leukemia, 2002,16(5) :833-839.
-
4Preisler HD, Gopal V. Regrowth resistance in leukemia and lymphoma: the need for a new system to classify treatment failure and for new approaches to treatment [J]. Leuk Res,1994,18(3): 149-160.
-
5Estey E. Treatment of refractory AML [J]. Leukemia, 1996,10(6) :932-936.
-
6Kottaridis PD, Gale RE, Langabeer SE, et al. Studies of FLT3 mutations in paired presentation and relapse samples from patients with acute myeloid leukemia:implications for the role of FLT3 mutations in leukemogenesis, minimal residual disease detection, and possible therapy with FLT3 inhibitors [J].Blood, 2002, 100(7) :2393-2398.
-
7Schaeffer HJ, Catling AD, Eblen ST, et al. MP1: a MEK binding partner that enhances enzymatic activation of the MAP kinase cascade [J]. Science, 1998,281 (5383): 1668-1671.
-
8Staber PB, Linkesch W, Zauner D, et al. Common alterations in gene expression and increased proliferation in recurrent acute myeloid leukemia [J]. Oncogene, 2004,23 (4):894-904.
-
9Estrov Z, Shishodia S, Faderl S, et al. Resveratrol blocks interleukin-1β-induced activation of the nuclear transcription factor NF-κB, inhibits proliferation, causes S-phase arrest, and induces apoptosis of acute myeloid leukemia cells [J]. Blood,2003,102(3) :987-995.
-
10Raza A, Preisler HD, Day R, et al. Direct relationship between remission duration in acute myeloid leukemia and cell cycle kinetics. A leukemia intergroup study [J]. Blood, 1990,76(11):2191-2197.
共引文献89
-
1周莉,张川莉,王凌云,季杰.lncRNA NEAT1在急性髓系白血病患者外周血中的表达及其与预后的关系[J].现代医学,2020(5):573-578. 被引量:3
-
2张振会,李翠娜,陈磊,尹旭燕,陈伟,刘彦朝,韩聪慧.HCAG方案联合中药治疗复发难治性急性髓系白血病35例临床观察[J].世界最新医学信息文摘,2020(68):207-208.
-
3史立会,任杰,隰海静,牛川,王静,庞艳彬.诊断时中性粒细胞与淋巴细胞比值作为急性髓系白血病复发风险因素的分析[J].世界最新医学信息文摘,2020(6):111-112.
-
4何琛,甘思林,刘延方,谢新生,孙慧.FLAG与MEA方案治疗复发、难治成年人急性髓系白血病的临床观察[J].白血病.淋巴瘤,2012,21(10):598-600. 被引量:1
-
5吴倩,何广胜,吴德沛,孙爱宁,仇惠英,金正明,苗瞄,唐晓文,韩悦,沈益民,陈峰,胡晓慧,金松,张旭辉.地西他滨桥接异基因造血干细胞移植治疗骨髓增生异常综合征和急性髓样白血病的临床可行性和疗效研究[J].肿瘤,2013,33(3):264-270. 被引量:5
-
6杨永,计成阜,张彦明,刘立民,何广胜,金正明,马骁,薛胜利,何雪峰,吴德沛,孙爱宁.IAG预激方案治疗复发、难治性急性髓系白血病临床分析[J].中华血液学杂志,2013,34(7):637-638. 被引量:5
-
7张洁,李娜,千新来.MDR-1与GST-π在柔红霉素诱导Kasumi-1细胞耐药中的作用[J].医药导报,2013,32(8):1015-1017.
-
8曾华.CAG方案治疗复发急性髓系白血病的疗效及安全性分析[J].安徽医学,2013,34(8):1162-1164. 被引量:2
-
9陈猛,张丽,潘崚.复发难治性急性髓系白血病诊疗进展[J].白血病.淋巴瘤,2013,22(9):524-527. 被引量:9
-
10吴迪炯,叶宝东,沈建平,沈一平,林圣云,胡致平,俞庆宏,郑智茵,彭来君,刘珊,季聪华,罗赟文,邵科钉,张宇,高雁婷,陈丹,周郁鸿.小剂量HA/HAA方案诱导治疗老年急性髓系白血病临床观察[J].中华血液学杂志,2014,35(3):256-259. 被引量:14
-
1王贤,夏永泉,张燕,张葵.116例急性髓系白血病免疫表型特点分析[J].山东医药,2012,52(44):84-86.
-
2郑卓军,朱远东,谢晓宝,蒋敬庭.地西他滨联合HIA方案治疗复发难治性急性髓系白血病的临床观察[J].临床肿瘤学杂志,2016,21(10):889-892. 被引量:9
-
3韩晓黎,江涛.SURVIVIN与肺癌[J].临床肺科杂志,2004,9(4):381-383. 被引量:1
-
4王高雄,李新丰,陈凌岩,叶超平.原发性肝癌术后复发的外科治疗(附160例报告)[J].福建医药杂志,2005,27(3):49-51.
-
5张曦,常春康,赵佑山,郭娟,费诚明,李晓.HIA与IA方案治疗初治急性髓系白血病的临床对比观察[J].肿瘤防治研究,2013,40(6):541-546. 被引量:7
-
6王亮,范立侨,李勇,宋振川,赵群,王力利.HLA-G在胃癌患者外周血及癌组织中的表达与临床意义[J].内蒙古医学杂志,2012,44(4):394-396.
-
7王建英,许茜,吴淑娟,李勇,程建新.卵巢恶性肿瘤组织中HLA-G、HLA-E的表达及意义[J].山东医药,2010,50(15):1-3. 被引量:6
-
8吴尘轩,杜智,高英堂,王毅军,朱争艳.β_2-微球蛋白mRNA低表达在肝细胞癌免疫逃逸中的作用[J].生物技术通讯,2007,18(6):921-923. 被引量:3
-
9苏毅,赖思含,易海,付利,范方毅,孙浩平,刘阳阳,邓涛,王译,何光翠.异基因造血干细胞移植术治疗自体造血干细胞移植术后复发的恶性淋巴瘤17例效果分析[J].第三军医大学学报,2012,34(24):2456-2458. 被引量:2
-
10左朝晖,李永国,蒋宏平,黄生福,李清龙.原发性肝癌伴胆管癌栓的诊治[J].中国普通外科杂志,2004,13(3):170-172. 被引量:5